TITLE

The relationship between the success rate of empirical antifungal therapy with intravenous itraconazole and clinical parameters, including plasma levels of itraconazole, in immunocompromised patients receiving itraconazole oral solution as prophylaxis: a multicenter, prospective, open-label, observational study in Korea

AUTHOR(S)
Kim, Jin; Cheong, June-Won; Kim, Yeo-Kyeoung; Park, Jinny; Mun, Yeung-Chul; Kang, Hye; Yi, Hyeon; Lee, Je-Hwan; Kim, Yang; Ryoo, Hun-Mo; Kim, Sung-Hyun; Kim, Ho; Lee, Dong-Gun; Kim, Hoon-Gu; Kim, Hawk; Joo, Young-Don; Min, Yoo
PUB. DATE
January 2014
SOURCE
Annals of Hematology;Jan2014, Vol. 93 Issue 1, p33
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
To identify the role of therapeutic drug monitoring of itraconazole (ITZ) in the setting of empirical antifungal therapy with intravenous (IV) ITZ, we performed a multicenter, prospective study in patients with hematological malignancies who had received antifungal prophylaxis with ITZ oral solution (OS). We evaluated the plasma levels of ITZ and hydroxy (OH) ITZ both before initiation of IV ITZ and on days 5-7 of IV ITZ. A total of 181 patients showed an overall success rate of 68.0 %. Prolonged baseline neutropenia and accompanying cardiovascular comorbidity were significantly associated with poor outcomes of the empirical antifungal therapy ( P = 0.005 and P = 0.001, respectively). A significantly higher trough plasma level of OH ITZ per body weight was found in the patients who achieved success with empirical antifungal therapy ( P = 0.036). There were no significant correlations between plasma concentrations of ITZ/OH ITZ (baseline or trough levels) and toxicities. Seven patients had a discontinuation of ITZ therapy due to toxicity. This study demonstrated that IV ITZ as empirical antifungal therapy was effective and therapeutic drug monitoring was helpful to estimate the outcome of empirical antifungal therapy in patients receiving antifungal prophylaxis with ITZ OS. To predict the outcome of empirical antifungal therapy with IV ITZ, we should evaluate baseline clinical characteristics and also perform the therapeutic drug monitoring of both ITZ and OH ITZ.
ACCESSION #
93391775

 

Related Articles

  • Topics in Infectious Diseases. Ellickalputhenpura, Bena E.; Torres, Harrys A. // JAAPA: Journal of the American Academy of Physician Assistants (;Dec2012, Vol. 25 Issue 12, p18 

    The article describes the pathophysiology and management of histoplasmosis, an infectious disease caused by inhalation of microconidia of Histoplasma capsulatum. It reports that the symptoms of it include asymptomatic, pulmonary, disseminated histoplasmosis. It highlights that bronchoalveolar...

  • Survival following lung resection in immunocompromised patients with pulmonary invasive fungal infection. Wu, Geena X.; Khojabekyan, Marine; Jami Wang; Tegtmeier, Bernard R.; O'Donnell, Margaret R.; Jae Y. Kim; Grannis, Frederic W.; Raz, Dan J. // European Journal of Cardio-Thoracic Surgery;Jan2016, Vol. 49 Issue 1, p314 

    OBJECTIVES: Pulmonary invasive fungal infections (IFIs) are associated with high mortality in patients being treated for haematological malignancy. There is limited understanding of the role for surgical lung resection and outcomes in this patient population. METHODS: This is a retrospective...

  • Delayed-release Posaconazole Tablets Offer Increased Exposure in a Fasted State. Lindsay, Caroline A. // Infectious Disease Alert;Apr2014, Vol. 33 Issue 7, p76 

    The article focuses on Posaconazole delayed-released tablets that was recently approved for prophylaxis of invasive Aspergillus and Candida infections in immunocompromised patients at least 13 years of age. It notes that these new delayed-release tablets produce superior drug exposure than the...

  • Coccidioidal Tenosynovitis of the Hand and Wrist: Report of 9 Cases and Review of the Literature. Campbell, Mark; Kusne, Shimon; Renfree, Kevin J.; Vikram, Holenarasipur R.; Smilack, Jerry D.; Seville, Maria T.; Orenstein, Robert; Blair, Janis E. // Clinical Infectious Diseases;11/15/2015, Vol. 61 Issue 10, p1514 

    Background. Tenosynovitis is an uncommon manifestation of disseminated infection with Coccidioides fungal species. Most experts treat this infection with combined surgical debridement and antifungal medication. The aim of our study was to examine the outcomes of patients with coccidioidal...

  • Intraocular penetration of voriconazole and caspofungin in a patient with fungal endophthalmitis. Spriet, Isabel; Delaere, Lien; Lagrou, Katrien; Peetermans, Willy E.; Maertens, Johan; Willems, Ludo // Journal of Antimicrobial Chemotherapy (JAC);Oct2009, Vol. 64 Issue 4, p877 

    The article presents a study that deals with the use of voriconazole and caspofungin in a patient with fungal endophthalmitis. The patient underwent 52 days of combination therapy using systemic voriconazole with therapeutic intraocular concentrations. A switch to posaconazole orally was made...

  • Antifungal socks as part of a regime to prevent recurrence of tinea pedis and onychomycosis. Bristow, Ivan; Turner, Anne // Podiatry Now;Oct2009, Vol. 12 Issue 10, p27 

    The article presents a case study of a 59-year-old male with a long history of chronic onychomycosis and tinea pedis of the toenail. The patient had previously been able to successfully control the infection through the use of oral itraconazole but upon completion of the therapy, re-infection...

  • Fatal Breakthrough Mucormycosis in an Acute Myelogenous Leukemia Patient while on Posaconazole Prophylaxis. Seung Hun Kang; Hyun Seon Kim; Myoung Nam Bae; Jihye Kim; Ji Yeon Yoo; Kwan Yong Lee; Dong-Gun Lee; Hee-Je Kim // Infection & Chemotherapy;Mar2015, Vol. 47 Issue 1, p49 

    Posaconazole is a new oral triazole with broad-spectrum antifungal activity. Posaconazole has also shown a significant advantage of preventing invasive fungal infection compared to fluconazole or itraconazole in patients with prolonged neutropenia. Indeed, posaconazole has been commonly used for...

  • THE TREATMENT OF COCCIDIOIDOMYCOSIS. AMPEL, Neil M. // Revista do Instituto de Medicina Tropical de Sao Paulo;Sep2015 Supplement, Vol. 57, p51 

    Therapy of coccidioidomycosis continues to evolve. For primary pulmonary disease, antifungal therapy is frequently not required while prolonged courses of antifungals are generally needed for those in whom extrathoracic disseminated has occurred. Intravenous amphotericin B should be reserved for...

  • How Many Steps along the Path Is Too Far? Drusano, G. L. // Clinical Infectious Diseases;1/1/2010, Vol. 50 Issue 1, p37 

    The author reflects on the study conducted by M. Neely and colleagues regarding the disposition of voriconazole in children diagnosed or suspected having a fungal infection. He argues that the study was retrospective as other have also reported relationships between voriconazole measurements and...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics